AU2003207646C1 - Treating stress response with chemokine receptor CCR5 modulators - Google Patents

Treating stress response with chemokine receptor CCR5 modulators Download PDF

Info

Publication number
AU2003207646C1
AU2003207646C1 AU2003207646A AU2003207646A AU2003207646C1 AU 2003207646 C1 AU2003207646 C1 AU 2003207646C1 AU 2003207646 A AU2003207646 A AU 2003207646A AU 2003207646 A AU2003207646 A AU 2003207646A AU 2003207646 C1 AU2003207646 C1 AU 2003207646C1
Authority
AU
Australia
Prior art keywords
subject
ccr5
response
administration
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003207646A
Other languages
English (en)
Other versions
AU2003207646A1 (en
AU2003207646B2 (en
Inventor
Agnes M. Azimzadeh
Julie A. Demartino
Richard N. Pierson III
Carsten Schroeder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University, Merck and Co Inc filed Critical Vanderbilt University
Publication of AU2003207646A1 publication Critical patent/AU2003207646A1/en
Application granted granted Critical
Publication of AU2003207646B2 publication Critical patent/AU2003207646B2/en
Publication of AU2003207646C1 publication Critical patent/AU2003207646C1/en
Assigned to VANDERBILT UNIVERSITY reassignment VANDERBILT UNIVERSITY Request for Assignment Assignors: MERCK & CO., INC., VANDERBILT UNIVERSITY
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003207646A 2002-01-22 2003-01-22 Treating stress response with chemokine receptor CCR5 modulators Ceased AU2003207646C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35086802P 2002-01-22 2002-01-22
US60/350,868 2002-01-22
US36509702P 2002-03-18 2002-03-18
US60/365,097 2002-03-18
PCT/US2003/001874 WO2003061659A1 (en) 2002-01-22 2003-01-22 Treating stress response with chemokine receptor ccr5 modulators

Publications (3)

Publication Number Publication Date
AU2003207646A1 AU2003207646A1 (en) 2003-09-18
AU2003207646B2 AU2003207646B2 (en) 2007-01-25
AU2003207646C1 true AU2003207646C1 (en) 2008-09-18

Family

ID=27616781

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003207646A Ceased AU2003207646C1 (en) 2002-01-22 2003-01-22 Treating stress response with chemokine receptor CCR5 modulators

Country Status (6)

Country Link
US (1) US20050079176A1 (enExample)
EP (1) EP1469849A4 (enExample)
JP (1) JP2005529067A (enExample)
AU (1) AU2003207646C1 (enExample)
CA (1) CA2472682A1 (enExample)
WO (1) WO2003061659A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2507704A1 (en) * 2002-12-02 2004-06-17 Mars, Incorporated Flavanols and procyanidins promote homeostasis
ES2431524T3 (es) 2004-04-13 2013-11-26 Incyte Corporation Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas
EP2493889B1 (en) 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
MX344600B (es) 2011-06-27 2016-12-20 Janssen Pharmaceutica Nv Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina.
WO2013071061A1 (en) * 2011-11-11 2013-05-16 The Children's Hospital Of Philadelphia Compositions and methods for increasing stress resilience
HK1206250A1 (en) 2012-06-26 2016-01-08 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders
CN104411314B (zh) 2012-07-09 2017-10-20 詹森药业有限公司 磷酸二酯酶10的抑制剂
EP3143005B1 (en) * 2014-05-16 2021-07-07 Emory University Chemokine cxcr4 and ccr5 receptor modulators and used related thereto
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042852A1 (en) * 1999-01-25 2000-07-27 Smithkline Beecham Corporation Compounds and methods
WO2000076972A1 (en) * 1999-06-11 2000-12-21 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
WO2001051077A1 (en) * 2000-01-14 2001-07-19 The Government Of The United States Of Americarep Resented By The Secretary, Department Of Health And Human Services Methods of regulating il-12 production by administering ccr5 agonists and antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0927167A1 (en) * 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AR011057A1 (es) * 1997-01-08 2000-08-02 Smithkline Beecham Corp Uso de bis-acridinas sustituidas y compuestos afines para la preparacion de medicamentos y dichos compuestos
AU9019098A (en) * 1997-08-15 1999-03-08 Advanced Research And Technology Institute, Inc. Functional characterization of the c-c chemokine-like molecules encoded by molluscum contagiosum virus types 1 and
JP2000020198A (ja) * 1998-07-06 2000-01-21 Fujitsu Ltd 端末制御方法及びそれを用いた端末装置並びにそれを実現するプログラムを記録したコンピュータ読み取り可能な記録媒体
US6358979B1 (en) * 1999-06-11 2002-03-19 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
AU2001253495A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Treating graft rejection with ccr5 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042852A1 (en) * 1999-01-25 2000-07-27 Smithkline Beecham Corporation Compounds and methods
WO2000076972A1 (en) * 1999-06-11 2000-12-21 Merck & Co., Inc. N-cyclopentyl modulators of chemokine receptor activity
WO2001051077A1 (en) * 2000-01-14 2001-07-19 The Government Of The United States Of Americarep Resented By The Secretary, Department Of Health And Human Services Methods of regulating il-12 production by administering ccr5 agonists and antagonists

Also Published As

Publication number Publication date
JP2005529067A (ja) 2005-09-29
US20050079176A1 (en) 2005-04-14
WO2003061659A1 (en) 2003-07-31
EP1469849A1 (en) 2004-10-27
CA2472682A1 (en) 2003-07-31
EP1469849A4 (en) 2007-06-27
AU2003207646B2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
US20030017150A1 (en) Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
JP4544639B2 (ja) αＶβ５仲介血管形成の阻止に有効な方法及び組成物
US7521206B2 (en) Anti-TNF antibodies, compositions, methods and uses
CN101253199B (zh) 免疫调节肿瘤坏死因子受体25(tnfr25)的激动剂、拮抗剂和免疫毒素
CA2994253C (en) Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
JPH04316600A (ja) Ｃｄ２５結合分子
US20020018776A1 (en) Method of treating graft rejection using inhibitors of CXCR3 function
US20060246073A1 (en) Anti-TNF antibodies and peptides of human tumor necrosis factor
US20070196373A1 (en) Anti-TNF antibodies and peptides of human tumor necrosis factor
JP5394916B2 (ja) Ｎｋｇ２ｄの調節方法
AU2003207646C1 (en) Treating stress response with chemokine receptor CCR5 modulators
RS51197B (sr) Anti-dual integrinska antitela, sastavi, metode i njihove upotrebe
EP2182943B1 (en) Methods and compositions for treating fibrosis related disorders using il-17 antagonists
US20020042370A1 (en) Method of treating graft rejection using inhibitors of CCR2 function
AU2003207646A1 (en) Treating stress response with chemokine receptor CCR5 modulators
US6538028B1 (en) Method for inhibiting complement activation
US20020019345A1 (en) Method of treating graft rejection using inhibitors of CCR5 function
US20090297502A1 (en) Ccr2 antagonists for chronic organ transplantation rejection
MXPA04004491A (es) Modulacion de funcion de receptores similares a inmunoglobulina leucocitaria para tratar artritis reumatoide.
US20010055594A1 (en) Use of certain drugs for treating nerve root injury
Debets et al. Inhibitory effect of corticosteroids on the secretion of tumour necrosis factor (TNF) by monocytes is dependent on the stimulus inducing TNF synthesis
US7959918B2 (en) Methods for treating vascular disease
Hess et al. The effect of the CD28 activation pathway on the immunosuppressive action of cyclosporine
Parissis et al. Cytokines and anti-cytokine therapeutic approaches to chronic heart failure
WO1999015200A1 (fr) COMPOSITION MEDICINALE DONT LE PRINCIPE ACTIF EST UN INHIBITEUR DE LIAISON DE gp34

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 MAR 2008.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 MAR 2008

PC Assignment registered

Owner name: VANDERBILT UNIVERSITY

Free format text: FORMER OWNER WAS: MERCK & CO., INC.; VANDERBILT UNIVERSITY

MK14 Patent ceased section 143(a) (annual fees not paid) or expired